Revive Therapeutics Announces Strategic Expansion of Bucillamine Program Across Infectious Diseases, Defence and Biothreat Medical Countermeasures

by rvvadmin | May 20, 2026 | 2026

Company to advance additional preclinical studies and pursue government partnership opportunities for bucillamine as a potential franchise asset for infectious diseases, nerve-agent exposure, future pandemics and medical countermeasure stockpiling TORONTO, ON / May...

Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases

by rvvadmin | Mar 11, 2026 | 2026

Patent momentum expands Revive’s bucillamine franchise across medical countermeasures, infectious diseases and additional high-value strategic applications TORONTO, ON /  March 11, 2026 / Revive Therapeutics Ltd. (“Revive” or the...

Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study

by rvvadmin | Dec 15, 2025 | 2025

TORONTO, Dec. 15, 2025 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases and medical...

Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study

by rvvadmin | Nov 21, 2025 | 2025

TORONTO, Nov. 21, 2025 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases and medical...

Revive Therapeutics Announces Closing of Second Tranche of Private Placement

by rvvadmin | Sep 19, 2025 | 2025

TORONTO, Sept. 19, 2025 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to developing innovative therapeutics for critical medical needs, announces that it has closed...